While uterine cancer quietly became the sixth most common cancer in women worldwide, claiming over 400,000 new diagnoses in 2020, understanding its global footprint and the factors driving its rise is the first step toward reversing this trend.
Key Takeaways
- In 2023, an estimated 66,470 new cases of uterine corpus cancer will be diagnosed in the United States, accounting for 3.0% of all new female cancer cases
- Globally, uterine cancer was the 6th most common cancer in women in 2020 with 417,367 new cases, representing 3.1% of all female cancers
- In the US, the age-adjusted incidence rate for uterine corpus cancer was 27.5 per 100,000 women per year based on 2017–2021 rates
- Obesity increases endometrial cancer risk by 2-4 times, with risk rising exponentially with BMI over 25
- Type 2 diabetes mellitus is associated with a 2.0-3.0 fold increased risk of endometrial cancer
- Nulliparity (never having given birth) raises endometrial cancer risk by 1.8-3.0 times compared to women with 3+ births
- The most common symptom of uterine cancer is abnormal vaginal bleeding, occurring in 90% of postmenopausal cases
- Transvaginal ultrasound detects endometrial thickness >4mm in postmenopausal women with bleeding, sensitivity 96% for cancer
- Endometrial biopsy has a sensitivity of 90-99% for detecting endometrial cancer in women with bleeding
- Total hysterectomy with salpingo-oophorectomy is standard for Stage I, performed in 80% of cases
- Adjuvant radiation therapy reduces local recurrence by 50% in intermediate-risk Stage I
- Chemotherapy with carboplatin-paclitaxel standard for advanced disease, response rate 40-60%
- 5-year overall survival for all stages uterine cancer in US is 84%
- Stage I endometrial cancer 5-year survival is 93-95%
- US uterine cancer mortality rate 2021-2025 projected 5,200 deaths
Uterine cancer is a common female cancer with varying global incidence and strong survival when caught early.
Epidemiology
1In 2023, an estimated 66,470 new cases of uterine corpus cancer will be diagnosed in the United States, accounting for 3.0% of all new female cancer cases
Verified2Globally, uterine cancer was the 6th most common cancer in women in 2020 with 417,367 new cases, representing 3.1% of all female cancers
Verified3In the US, the age-adjusted incidence rate for uterine corpus cancer was 27.5 per 100,000 women per year based on 2017–2021 rates
Verified4Uterine cancer incidence rates in the US increased by 0.6% annually from 2012 to 2021, with a sharper rise of 1.9% per year among Black women
Directional5In Europe, the age-standardized incidence rate of uterine cancer was 13.7 per 100,000 women in 2020, varying from 5.4 in Eastern Europe to 18.2 in Northern Europe
Single source6Among Hispanic women in the US, uterine cancer incidence rose by 2.7% annually between 2007 and 2016
Verified7In 2022, approximately 65,950 women in the US were diagnosed with endometrial cancer
Verified8The lifetime risk of developing uterine cancer for US women is about 3.1% (1 in 32)
Verified9In the UK, there were 10,253 new uterine cancer cases in 2020, making it the 4th most common female cancer
Directional10Uterine cancer prevalence in the US reached 873,436 cases in 2022
Single source11In Japan, uterine corpus cancer incidence is 24.7 per 100,000 women, lower than Western countries due to lower obesity rates
Verified12Among US Asian/Pacific Islander women, uterine cancer incidence is 14.5 per 100,000
Verified13In Australia, 2,313 new uterine cancer cases were diagnosed in 2021, with an ASR of 20.5 per 100,000
Verified14Uterine cancer incidence in non-Hispanic white US women is 28.2 per 100,000
Directional15In India, uterine cancer accounts for 4.4% of female cancers with 21,115 cases in 2020
Single source16US uterine cancer diagnoses peaked at ages 70-74 with rates of 142 per 100,000
Verified17In Brazil, 2020 saw 13,881 new uterine cancer cases, ASR 12.3 per 100,000 women
Verified18Among US Black women, uterine cancer incidence is 24.4 per 100,000, higher mortality despite lower incidence
Verified19In Canada, 7,300 new uterine cancer cases expected in 2023
Directional20Global uterine cancer cases projected to reach 1.5 million by 2050 due to aging and obesity
Single source21In Sweden, uterine cancer incidence rate is 30.4 per 100,000 women (2020)
Verified22US uterine cancer 5-year limited duration prevalence is 4.7% of female cancer survivors
Verified23In China, 148,557 new uterine cancer cases in 2022, ASR 15.4 per 100,000
Verified24Among postmenopausal US women, 90% of uterine cancers occur post-menopause
Directional25In the Netherlands, uterine cancer incidence rose 2.3% annually from 1989-2019
Single source26US American Indian/Alaska Native women have uterine cancer incidence of 15.8 per 100,000
Verified27In France, 9,582 new uterine cancer cases in 2020
Verified28Global variation shows highest uterine cancer ASRs in North America (30.7 per 100,000)
Verified29In 2021, US SEER data showed 42,530 invasive uterine corpus cancers diagnosed
DirectionalEpidemiology Interpretation
While these numbers may seem like a dry constellation of statistics, they tell a sobering and expanding story: uterine cancer is a pervasive global health issue whose rising incidence, particularly among Black and Hispanic women in the US, is a silent alarm demanding our attention beyond the 3% of female cancers it represents.
Prognosis and Mortality
15-year overall survival for all stages uterine cancer in US is 84%
Verified2Stage I endometrial cancer 5-year survival is 93-95%
Verified3US uterine cancer mortality rate 2021-2025 projected 5,200 deaths
Verified4Black women have 37% higher uterine cancer mortality than white women
Directional510-year survival for localized uterine cancer is 89%
Single source6Global uterine cancer deaths in 2020: 97,370, ASR 2.3 per 100,000
Verified7Stage IV 5-year survival 17-20%
Verified8Mortality rates increased 2.0% annually 2007-2016 for Black women
Verified9Grade 1 endometrioid tumors 5-year OS 90-95%
Directional10Uterine serous carcinoma 5-year survival 45-50% despite early stage
Single source11Distant stage 5-year survival 18%
Verified12In UK, 5-year net survival for uterine cancer 77% (2016-2020)
Verified13Recurrence rate for Stage I high-intermediate risk 20-25% without adjuvant RT
Verified14MMR-deficient tumors have better prognosis, 5-year OS 75% vs 60%
Directional15Age >60 years halves 5-year survival to 50%
Single source16Lymphovascular space invasion increases recurrence risk 3-fold
Verified1715-year relative survival for localized disease 81%
Verified18Clear cell carcinoma 5-year survival 40%, poorest among subtypes
Verified19Australia 5-year survival 83% for uterine cancer (2016-2020)
Directional20Deep myometrial invasion (>50%) drops Stage I survival to 80%
Single source21Positive peritoneal cytology worsens prognosis by 10-15% OS reduction
Verified22Canada uterine cancer 5-year survival 74%
Verified23Median survival for recurrent disease 12-24 months with treatment
Verified24p53 abnormal tumors have 40% 5-year survival vs 80% wild-type
Directional25Stage III 5-year survival 50-60%
Single source26Obesity paradoxically improves surgical prognosis but worsens cancer-specific
Verified27Japan 5-year survival 82% for endometrial cancer
VerifiedPrognosis and Mortality Interpretation
While we have made impressive progress, boasting survival rates as high as 95% for some, the cold truth is that these statistics betray a profound inequality, where a black woman's diagnosis or a rarer, more aggressive tumor type can drastically rewrite her odds in a system that hasn't protected everyone equally.
Risk Factors
1Obesity increases endometrial cancer risk by 2-4 times, with risk rising exponentially with BMI over 25
Verified2Type 2 diabetes mellitus is associated with a 2.0-3.0 fold increased risk of endometrial cancer
Verified3Nulliparity (never having given birth) raises endometrial cancer risk by 1.8-3.0 times compared to women with 3+ births
Verified4Postmenopausal hormone therapy with estrogen alone (without progestin) increases risk by 2-10 times depending on duration
Directional5Polycystic ovary syndrome (PCOS) is linked to a 2.5-3.0 fold higher risk of endometrial cancer due to chronic anovulation
Single source6Late menopause (after age 52) increases risk by 1.5-2.0 times due to prolonged estrogen exposure
Verified7Early menarche (before age 12) associated with 1.5-fold increased endometrial cancer risk
Verified8Hereditary nonpolyposis colorectal cancer (HNPCC/Lynch syndrome) confers 40-60% lifetime risk of endometrial cancer
Verified9Tamoxifen use for breast cancer treatment increases endometrial cancer risk by 2-7 times
Directional10Hypertension is associated with 1.4-1.7 fold increased risk of endometrial cancer
Single source11Family history of endometrial or colorectal cancer doubles the risk
Verified12Smoking reduces endometrial cancer risk by 20-30% in postmenopausal women
Verified13Physical inactivity increases risk by 20-40%, with sedentary lifestyle OR of 1.3-1.5
Verified14Breastfeeding reduces risk by 10-20% per year of breastfeeding
Directional15Oral contraceptive use decreases risk by 30-50% with 5+ years use, effect lasting 20+ years post-use
Single source16Metabolic syndrome components (obesity, diabetes, hypertension) synergistically increase risk up to 4-fold
Verified17BRCA1 mutation carriers have 2-3 fold higher endometrial cancer risk compared to non-carriers
Verified18High glycemic load diet associated with 1.5-2.0 fold risk increase
Verified19Estrogen-producing ovarian tumors increase risk dramatically, up to 20-fold
Directional20Alcohol consumption shows inverse association, reducing risk by 10-20% in moderate drinkers
Single source21Prior pelvic radiation therapy increases risk by 2-4 times
Verified22Coffee consumption (4+ cups/day) linked to 20-25% risk reduction
Verified23Vitamin D deficiency associated with 1.5-fold increased risk
Verified24Endometrial hyperplasia without atypia progresses to cancer in 1-3% of cases
Directional25Atypical endometrial hyperplasia has 20-30% progression rate to endometrial cancer
Single source26Obesity BMI >40 increases risk 7-fold compared to normal weight
VerifiedRisk Factors Interpretation
It seems the uterus keeps a meticulous, often ironic ledger: while life blesses us with childbirth and coffee as modest shields, it cruelly multiplies the bill through obesity, diabetes, and estrogen's unopposed reign, reminding us that our most profound reproductive risks are often woven from the very threads of modern living.
Symptoms and Diagnosis
1The most common symptom of uterine cancer is abnormal vaginal bleeding, occurring in 90% of postmenopausal cases
Verified2Transvaginal ultrasound detects endometrial thickness >4mm in postmenopausal women with bleeding, sensitivity 96% for cancer
Verified3Endometrial biopsy has a sensitivity of 90-99% for detecting endometrial cancer in women with bleeding
Verified4Pelvic pain occurs in 20-30% of advanced uterine cancer cases
Directional5CA-125 tumor marker is elevated in 25-50% of women with advanced endometrial cancer
Single source6Hysteroscopy allows direct visualization and biopsy, with 90-95% sensitivity for endometrial pathology
Verified7Watery or bloody discharge occurs in 10-15% of premenopausal uterine cancer patients
Verified8MRI staging accuracy for deep myometrial invasion is 85-95%, superior to CT
Verified9Postmenopausal bleeding prompts 90% of endometrial cancer diagnoses
Directional10PET-CT has 90% sensitivity for detecting lymph node metastases in high-risk cases
Single source11Lower abdominal pain reported in 25% of symptomatic uterine cancer patients
Verified12Endometrial sampling false-negative rate is 5-10% due to sampling error
Verified13Unintentional weight loss occurs in 10-20% of advanced cases
Verified14Saline infusion sonography improves detection of focal lesions, sensitivity 92%
Directional15Fatigue and anemia from bleeding seen in 15% of diagnosed patients
Single source16FIGO staging system used in 95% of cases, with Stage I comprising 75% of diagnoses
Verified17Dysuria or hematuria in 5-10% due to bladder involvement
Verified18Office endometrial biopsy success rate 87-97% in postmenopausal women
Verified19CT scan detects extrauterine disease with 70-80% accuracy
Directional20Vaginal bleeding in premenopausal women abnormal if heavy or intermenstrual in 75% suspicious cases
Single source21Sentinel lymph node biopsy mapping success 80-90% in early-stage disease
Verified22Pelvic mass palpable in only 5% of early-stage uterine cancers
Verified23HE4 biomarker elevated in 70% of Type II endometrial cancers
Verified24Dilation and curettage diagnostic yield 99% when biopsy inconclusive
Directional25Leg swelling from lymphatic obstruction in 10% advanced cases
Single sourceSymptoms and Diagnosis Interpretation
If your body starts writing checks your hormones can't cash—like any postmenopausal bleeding or wildly irregular premenopausal flow—consider it a serious memo to investigate, because while the diagnostic tools are impressively sharp, from ultrasound's watchful eye to biopsy's precise verdict, catching this early, when it's often stage one and highly treatable, is what turns a staggering statistic into a survivable story.
Treatment
1Total hysterectomy with salpingo-oophorectomy is standard for Stage I, performed in 80% of cases
Verified2Adjuvant radiation therapy reduces local recurrence by 50% in intermediate-risk Stage I
Verified3Chemotherapy with carboplatin-paclitaxel standard for advanced disease, response rate 40-60%
Verified4Vaginal brachytherapy for high-intermediate risk Stage I, recurrence risk reduced to 4%
Directional5Hormone therapy with progestins effective in 20-30% of low-grade advanced cases
Single source6Minimally invasive laparoscopic hysterectomy feasible in 70% of cases, with shorter hospital stay
Verified7Pembrolizumab immunotherapy shows 48% response in MSI-high/dMMR tumors
Verified8External beam radiation for Stage II-III, pelvic control 85-90%
Verified9Lenvatinib + pembrolizumab ORR 38% in advanced endometrial cancer
Directional10Neoadjuvant chemotherapy response 30-40% in high-risk operable cases
Single source11Robotic-assisted surgery reduces complications to 10% vs 20% open surgery
Verified12Dostarlimab achieves 42.3% response in dMMR recurrent cases
Verified13Lymphadenectomy in low-risk omitted in 60% per PORTEC-4a trial
Verified14Trastuzumab for HER2-positive uterine serous carcinoma, response 50%
Directional15Megestrol acetate for stage IV low-grade, stable disease in 25%
Single source16IMRT reduces bowel toxicity by 40% compared to conventional RT
Verified17Bevacizumab added to chemo improves PFS to 14.7 months vs 10.2
Verified18Fertility-sparing progestin therapy success 75% in stage IA grade 1 young women
Verified19PARP inhibitors like olaparib for BRCA-mutated, response 20-30%
Directional20Whole pelvic RT + brachytherapy for stage III, 5-year DFS 60%
Single source21Hysteroscopic resection for early lesions, complete response 80% in select cases
Verified22Atezolizumab + chemo PFS benefit 1.7 months in MMR-proficient
Verified23Sentinel node biopsy reduces lymphedema to 5% vs 20% full lymphadenectomy
Verified24Everolimus + letrozole PFS 8.5 months in advanced disease
Directional25Adjuvant chemo for serous/clear cell histology, OS benefit 10-15%
Single source26Proton therapy for recurrent pelvic disease, local control 80%
Verified27Hormonal intrauterine device (Mirena) prevents hyperplasia recurrence 90%
VerifiedTreatment Interpretation
We have evolved from one brutal cure to an arsenal of elegant, targeted strategies, trading blanket removal for precision strikes that turn our own defenses against the disease while preserving everything from fertility to bowel function.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2GCOgco.iarc.who.intVisit source
- Reference 3SEERseer.cancer.govVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5JOURNALSjournals.lww.comVisit source
- Reference 6CDCcdc.govVisit source
- Reference 7CANCERcancer.govVisit source
- Reference 8CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 9NCBIncbi.nlm.nih.govVisit source
- Reference 10AIHWaihw.gov.auVisit source
- Reference 11CANCERcancer.caVisit source
- Reference 12COCHRANELIBRARYcochranelibrary.comVisit source
- Reference 13MAYOCLINICmayoclinic.orgVisit source
- Reference 14AAFPaafp.orgVisit source
- Reference 15NEJMnejm.orgVisit source